Theriva Biologics TOVX Q1 2026 Earnings Slight EPS Beat Boosts Sentiment for ClinicalStage Biotech PURR Q1 2026 Earnings Strong EPS Beat Overshadowed by Revenue Uncertainty LGCY Q1 2026 Earnings EPS Beats Estimates by 244 Revenue Not Disclosed OCS Q1 2026 Earnings EPS Misses Estimates as Operating Losses Widen ZEPP Q3 2025 Earnings Narrowed Loss Amid Mixed Operational Signals Amphastar Pharmaceuticals AMPH Q1 2026 Earnings Significant EPS Miss Fails to Dampen Stock Sentiment